LACTOLOGY FOUNDATION

Belladonna alkaloids of the A03BB class (semisynthetic quaternary ammonium compounds) are peripherally acting antispasmodics with low central penetration and modest systemic bioavailability, which generally limits toxicity and transfer into breast milk, but standard antimuscarinic cautions still apply and data for individual drugs beyond hyoscine butylbromide are very limited. For lactation, short-term use of hyoscine butylbromide (butylscopolamine, A03BB01) is usually considered compatible with breastfeeding under monitoring, whereas parenteral and high-dose administration, or prolonged courses of any A03BB agent, should be avoided or individualized due to theoretical risks of anticholinergic effects in the infant and possible reduction in milk production.atcddd.fhi+5

Pharmacological group A03BB

A03BB comprises “belladonna alkaloids, semisynthetic, quaternary ammonium compounds”, classified under A03B (belladonna and derivatives, plain) within the WHO ATC system and used as gastrointestinal antispasmodics. The currently listed substances include butylscopolamine (hyoscine butylbromide, A03BB01), methylatropine (A03BB02), methylscopolamine (A03BB03), fentonium (A03BB04), cimetropium bromide (A03BB05) and homatropine methylbromide (A03BB06), with defined daily doses reflecting typical oral, parenteral or rectal use.atccode+4

These drugs are quaternary ammonium derivatives of tropane alkaloids (e.g. atropine, scopolamine) designed to act mainly on peripheral muscarinic receptors with reduced ability to cross the blood–brain barrier. They are indicated primarily for the relief of smooth muscle spasm in the gastrointestinal and genitourinary tracts, and some preparations are used in obstetric practice or as adjuncts in endoscopic and radiologic procedures.pharmassive+5

Mechanism of action

A03BB compounds act as competitive antagonists at peripheral muscarinic acetylcholine receptors, reducing parasympathetic tone in smooth muscle and thereby relieving spasm, decreasing motility and secretions. Because they are permanently charged quaternary ammonium compounds, their penetration into the central nervous system is poor, which lowers the risk of central anticholinergic effects compared with tertiary amines.fdaghana+4

Hyoscine butylbromide is the best-characterised representative and shows a rapid onset of spasmolytic action with limited systemic exposure after oral administration due to low bioavailability and high first-pass extraction. Similar peripheral antispasmodic activity is described for other members of the class, although comparative head‑to‑head data are scarce and most clinical experience is with butylscopolamine.e-lactancia+5

Pharmacokinetics

After oral dosing, hyoscine butylbromide has low systemic bioavailability (only a small fraction of the dose reaches the circulation) because of poor gastrointestinal absorption and extensive first‑pass metabolism, which contributes to its predominantly local action in the gut. Parenteral administration (intravenous or intramuscular) bypasses first‑pass metabolism and produces higher systemic concentrations, which are used in acute care settings to relieve severe spasm or facilitate procedures.droracle+3

Distribution is largely confined to peripheral tissues owing to the quaternary ammonium structure, with negligible penetration into the brain; elimination occurs via hepatic metabolism and biliary and renal excretion. Given the limited systemic exposure and short plasma half‑life, accumulation with standard intermittent dosing is unlikely in patients with normal organ function, although specific pharmacokinetic studies in lactating women are lacking.atccode+3

General toxicology

Hyoscine butylbromide demonstrates a relatively low acute toxicity in animal studies, with reported oral LD50 values in the range of approximately 1000–3000 mg/kg, far exceeding therapeutic doses. In humans, serious signs of poisoning after acute overdose are uncommon, but classical anticholinergic manifestations (dry mouth, flushed skin, tachycardia, urinary retention, ileus and transient visual disturbances) may appear at high doses, and Cheyne–Stokes respiration has been reported.fdaghana+1

Chronic toxicity data are limited, but class‑related precautions mirror those for other antimuscarinics: they are contraindicated in conditions such as narrow‑angle glaucoma, prostatic hypertrophy with urinary retention, mechanical or paralytic gastrointestinal obstruction, megacolon, tachyarrhythmias and myasthenia gravis. In overdose, treatment is supportive, with use of parasympathomimetics (e.g. physostigmine) in severe anticholinergic syndromes and specific measures such as catheterisation in urinary retention or topical pilocarpine in patients with glaucoma.e-lactancia+1

Maternal safety considerations

In non‑pregnant adults, A03BB drugs are generally well tolerated when used for short courses at recommended doses, with adverse effects largely reflecting peripheral anticholinergic actions. Commonly reported reactions include dry mouth, constipation, mild tachycardia, transient visual accommodation disturbances and, less frequently, urinary retention or skin flushing; hypersensitivity reactions and anaphylaxis are rare but described in post‑marketing surveillance.sps+2

For pregnancy, product characteristics for injectable hyoscine butylbromide note limited human data and insufficient animal reproductive toxicology, so routine use in pregnancy is not recommended as a precaution despite occasional obstetric use for shortening labour. The same documents emphasise that parenteral hyoscine butylbromide during breastfeeding is not recommended because a risk to the breastfed child cannot be excluded, underscoring the need to differentiate oral from parenteral routes in risk assessment.pmc.ncbi.nlm.nih+1

Lactation: pharmacokinetic and pharmacodynamic considerations

Because quaternary ammonium derivatives like hyoscine butylbromide are poorly absorbed orally and have low systemic availability, the amount that can transfer into breast milk after standard oral dosing is expected to be small. Even if small quantities reach milk, the infant’s gastrointestinal tract would absorb only limited amounts due to the same low oral bioavailability, suggesting a low likelihood of clinically relevant exposure in term infants.breastfeeding-and-medication+2

However, as antimuscarinic agents, these drugs have a theoretical potential to reduce prolactin-mediated lactation or to cause anticholinergic symptoms in the infant (e.g. dry mouth, constipation, urinary retention, tachycardia), especially if exposure is high (parenteral maternal use) or prolonged. Published guidance therefore recommends using the lowest effective dose for the shortest duration, avoiding repeated parenteral administration in breastfeeding women and monitoring infants for adequate feeding and weight gain when maternal antispasmodic therapy is needed.gpnotebook+1

Evidence and recommendations for hyoscine butylbromide (A03BB01)

Clinical and reference sources describe oral hyoscine butylbromide (Buscopan and equivalents) as generally compatible with breastfeeding when used short term at usual doses. The British National Formulary and lactation-focused resources report that the amount excreted into human milk appears too small to be harmful, especially given the drug’s poor oral bioavailability in the infant.gpnotebook+2

NHS‑affiliated guidance on gastrointestinal antispasmodics states that hyoscine butylbromide, alongside propantheline and peppermint oil, can be considered a preferred choice during breastfeeding, with the caveat of potential theoretical suppression of milk production. Specialist breastfeeding resources similarly classify Buscopan as compatible with breastfeeding, advising routine monitoring for infant side effects and maternal anticholinergic symptoms.breastfeeding-and-medication+2

Other A03BB agents (data extrapolation)

For methylatropine, methylscopolamine, fentonium, cimetropium bromide and homatropine methylbromide, direct human lactation data are extremely sparse or absent, so risk assessment relies on class extrapolation and their shared quaternary ammonium, peripherally acting antimuscarinic profile. Given this, it is reasonable to assume that oral formulations will also have low systemic bioavailability and limited milk transfer, but the absence of specific milk level and infant safety data warrants a more cautious, case‑by‑case approach than for hyoscine butylbromide.chemoinfo.ipmc.cnrs+3

In practice, when a quaternary antispasmodic is indicated in a breastfeeding woman, hyoscine butylbromide is usually preferred because of the relatively robust safety experience, while other A03BB agents should be reserved for situations where clinical benefit clearly outweighs theoretical risks and where alternative agents are unsuitable. For non‑hyoscine A03BB drugs, shorter treatment duration, minimal effective dosing and careful infant monitoring are prudent risk‑reduction strategies.sps+2

Practical lactology guidance

When considering A03BB therapy in breastfeeding women, oral hyoscine butylbromide at standard doses for acute or short-term indications (e.g. intestinal colic, biliary spasm) can generally be used with appropriate counselling and monitoring. Parenteral administration, high cumulative doses, or repeated long‑term courses should be avoided where possible, and alternative non‑anticholinergic strategies (e.g. non‑pharmacologic measures, other antispasmodics with more lactation data) should be considered first.fdaghana+3

During therapy, mothers should be advised to observe their infants for signs such as poor feeding, reduced weight gain, constipation, unusual drowsiness or irritability and decreased urine output, and to seek medical advice if these occur, particularly in premature or medically fragile infants. If maternal milk supply appears reduced or infant growth is suboptimal, discontinuation or substitution of the antispasmodic and support from a lactation specialist may be required.gpnotebook+1